ElevenLabs stock
Private-market facts for current and former ElevenLabs employees researching their stock.
Overview
AI voice technology company offering realistic text-to-speech, voice cloning, and audio dubbing tools for content creators and enterprises.
ElevenLabs outlook
For employees evaluating ElevenLabs equity, a 2x base multiple suggests limited near-term upside at current levels. The upside scenario at 3x is relatively close to the base case, suggesting more predictable but narrower range of outcomes.
These estimates reflect modeled return scenarios, not guaranteed outcomes. Actual results depend on company performance, market conditions, share class, and timing.
Selling ElevenLabs shares
Why shareholders consider selling
Shareholders in ElevenLabs may explore liquidity for a number of reasons — diversifying a concentrated position, funding a personal financial goal, or simply reducing exposure to a single private holding. As a private company, ElevenLabs does not trade on a public exchange, meaning employees and early shareholders cannot simply sell through a brokerage. Extended private timelines can leave shareholders waiting years for an exit event, which is why some choose to explore secondary-market options.
Can you sell ElevenLabs stock?
Whether a shareholder can sell typically depends on what they hold and how it was acquired. Vested and exercised shares are generally more straightforward than unexercised options or unvested RSUs. Most private companies, including those in the Artificial Intelligence sector, impose transfer restrictions such as rights of first refusal or board approval requirements. The specific terms governing ElevenLabs shares would be outlined in the holder's equity agreement or the company's governing documents.
What affects the value of ElevenLabs shares?
The price a buyer is willing to pay for private shares is shaped by several factors: overall demand for the stock, the company's financial performance, broader Artificial Intelligence market conditions, and any recent private-market transaction activity. Data points such as the company's Series C round and its reported $11B valuation can help frame expectations, though they do not guarantee a transaction price.
What should holders check before selling
- The type of security held (common shares, preferred, options, RSUs)
- Whether the equity is fully vested and, for options, whether it has been exercised
- Any transfer restrictions, lock-up provisions, or company approval requirements
- Estimated net proceeds after applicable taxes and transaction fees
- Whether partial liquidity — selling a portion rather than the full position — may be a better fit
Tools for ElevenLabs shareholders
Exploring equity in ElevenLabs often raises questions about taxes, exercise timing, valuation, and exit outcomes. These tools can help you model different decisions using your own assumptions.
Latest funding round
ElevenLabs most recently raised a Series C round in January 2025. The company was valued at $11B. Total funding raised to date is approximately $270M.
Lead investors in this round include Andreessen Horowitz and Sequoia Capital.
Founders & company background
ElevenLabs was founded in 2022 by Piotr Dabkowski, Mati Staniszewski and is headquartered in New York, NY.
Investors
Industry
Similar private companies
Latest ElevenLabs news
Frequently asked questions
- Is ElevenLabs still a private company?
- Yes, ElevenLabs is currently a private company.
- What is ElevenLabs's latest funding round?
- ElevenLabs's most recent known round is Series C, raised in January 2025.
- What is ElevenLabs's valuation?
- ElevenLabs's latest reported valuation is $11B.
- Who are the investors in ElevenLabs?
- Notable investors include Andreessen Horowitz, Sequoia Capital, Founders Fund, SV Angel, Smash Capital, ICONIQ Capital.
- Can I sell my ElevenLabs stock?
- Private company shares can sometimes be sold on secondary markets. Speaking with a specialist who understands ElevenLabs stock can help you evaluate your options.
Related pages
Last verified: 2026-04-13 · ElevenLabs data compiled from funding disclosures, investor announcements, corporate filings, and public records.
Information on this page is compiled from publicly available sources and may be outdated or incomplete. This is not investment advice. Consult a qualified advisor before making financial decisions.